Emm, a British biowearable startup focused on menstrual and reproductive health, has secured $9 million in an oversubscribed Seed round to advance what it calls the world’s first smart menstrual solution. The raise reflects both growing investor conviction in FemTech and the mounting appetite for data-rich consumer health devices. It also positions the Bristol-based company among the most significant early-stage players in Europe’s connected women’s health sector this year.
Funding Announcement
The Seed round was led by Lunar Ventures, with participation from the Labcorp Venture Fund, Tiny Supercomputer Investment Company, BlueLion Global, and Alumni Ventures, alongside high-profile angels including Amar Shah, Vivek Garipalli, and Harpreet Rai. Emm also secured non-dilutive grants supporting women’s health innovation, adding to the scale of resources fueling its development program. The company said the oversubscription demonstrates widening recognition that menstrual health is central to broader human health rather than a niche category.
Vision for a New Standard in Menstrual Health
Founder and CEO Jenny Button emphasized that menstruation is widely recognized as the fifth vital sign, yet remains largely ignored by mainstream wearable technology. She said that millions still lack objective, continuous data to understand their bodies or advocate for better care, something Emm aims to change. The company’s goal is to bring menstrual health into parity with cardiovascular and metabolic tracking by offering a reliable, personalized stream of insights.
Technology and Product Development
Emm’s device combines medical-grade silicone with ultra-thin sensor technology to create a non-intrusive menstrual cup capable of capturing high-fidelity data. The product has been developed over five years, incorporating thousands of design iterations and extensive user testing to ensure comfort, durability, and accuracy. The accompanying app automatically establishes baseline patterns within three cycles, enabling users to identify trends, make clearer decisions, and hold more informed discussions with clinicians.
Market Context in Europe
The raise comes during a notable uptick in European FemTech and connected-health investments in 2025. Recent activity includes €7.8 million for London-based Hormona, €250,000 for Dutch startup YON E Health, and €14 million for French MedTech player RDS. With roughly €22 million flowing into the category this year, Emm’s Seed round ranks among the largest at this stage and stands out for its focus on menstrual-specific biowearables.
Investor Perspectives
Grace E. Colón, PhD, Chair of the Board, said Emm’s platform could function both as a biological sampling tool and a data engine for researchers and biotech companies. She highlighted the opportunity to generate new scientific understanding in reproductive health, an area long overlooked by medical research. Investors believe the device could catalyze significant advances in diagnostics, monitoring, and long-term disease management.
Commercial Roadmap
The company plans to launch its product in the UK in early 2026, with additional markets expected shortly afterward. Emm has already opened a consumer waitlist as it accelerates clinical development and expands its data infrastructure. The funding will support regulatory progress, expand engineering capabilities, and prepare for large-scale manufacturing ahead of launch.
Broader Implications for Women’s Health
Emm’s leadership argues that menstrual and reproductive health remain among the most underserved areas in global healthcare despite affecting half the population. The company cites data showing that one in three women experiences severe menstrual or reproductive symptoms, yet reliable baseline tracking tools remain scarce. Emm aims to close this gap by providing objective measurements that can improve care quality, early detection, and long-term health outcomes.
By pairing advanced sensor engineering with consumer-friendly design, Emm is positioning itself to reshape how menstrual data is captured, interpreted, and used. The new investment gives the team momentum to bring its technology from prototype to commercial availability while driving research that has historically lacked robust datasets. As the FemTech landscape expands, Emm is preparing to lead a new class of biowearables that recognize menstrual health as foundational rather than peripheral to human wellbeing.